Pasithea TherapeuticsKTTA
13F holders, Q2 2025 (June 30)11holders +3
4new positions
1sold out
1famous investor
$0.72avg. 13F price*
At the end of Q2 2025, 11 institutions reported holding Pasithea Therapeutics Corp. (KTTA) in their 13F filings, up 3 from Q1 2025. 4 opened new positions and 1 sold out. The largest holders were AdvisorShares Investments LLC ($140K), Citadel Advisors ($34K) and UBS Group AG ($30K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Pasithea Therapeutics Corp.
- CUSIP
- 70261F202
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $43K |
| Exits | 1 | $18K |
All 13F filers, Q1 2025 → Q2 2025: 237,352 shares bought and 15,712 shares sold, net +221,640 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| AdvisorShares Investments LLC | 0.03% | Add +261.4% | 193,547 | $140K |
| Citadel Advisors | 0.00% | New | 46,858 | $34K |
| UBS Group AG | 0.00% | Add +871.7% | 42,142 | $30K |
| LPL Financial LLC | 0.00% | New | 10,000 | $7K |
| Hurley Capital, LLC | 0.00% | No change | 3,689 | $3K |
| Raymond James Financial Inc. | 0.00% | New | 1,584 | $1K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -61.4% | 1,261 | $910 |
| SBI Securities Co., Ltd. | 0.00% | New | 1,051 | $758 |
| JPMorgan Chase & Co. | 0.00% | No change | 150 | $108 |
| Bank of America Corp. | 0.00% | Add +675.0% | 62 | $44 |
| Royal Bank of Canada | 0.00% | No change | 250 | $0 |
"% of holder's portfolio" is KTTA's weight in each manager's 13F, not the share of Pasithea Therapeutics Corp. the manager owns.